+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-04-05Number of Pages: 103

Transdermal Scopolamine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Transdermal Scopolamine Market: Snapshot

The global market for transdermal scopolamine is witnessing a remarkable rise, thanks to rising awareness among consumers regarding it being highly effective in treating motion sickness. The increasing number of travelers across the world is adding substantially to the growth of this market. Transdermal scopolamine also finds application during surgeries as it helps in avoiding hyper salivation and aids in recovery from post-operative and anesthesia-induced nausea and vomiting. As a result of the noticeable rise in the number of surgeries performed globally, the demand for transdermal scopolamine has also increased considerably across the world.

Researchers expect this market to remain registering exceptional growth over the forthcoming years. However, the rising reports of side-effects, such as drowsiness, retarded motion, and diluted pupils while using transdermal scopolamine patches, may limit their uptake to some extent in the near future. Apart from this, the increasing cases of adverse withdrawal symptoms for transdermal scopolamine patches and the presence of stringent laws and regulations in manufacturing and marketing of transdermal scopolamine products may hinder the market’s growth in the long run. The market, which stood at a value of US$330.0 mn in 2015, is estimated to expand at a CAGR of 6.70% from 2016 to 2024 and reach US$585.3 mn by the end of 2024.

transdermal scopolamine market

North America to Remain Dominant Regional Market

Geographically, the worldwide transdermal scopolamine market is classified into Latin America, North America, the Middle East and Africa, Europe, and Asia Pacific. With a well-established healthcare industry, high healthcare expenditure, and soaring usage of transdermal scopolamine in surgeries and post-operative recovery, North America has been leading the global market.

Progressing at a CAGR of 6.40% between 2016 and 2024, the regional market is likely to retain its lead over the forthcoming years. Although transdermal scopolamine is off patent now – it was introduced in 1981 – it has very few generics available in the market, which is leading to a stagnancy in the North American market, pointing towards a moderate future growth. Europe, however, is expected to contribute significantly to the growth of the global market in the years to come. With a massive number of travelers and a state-of-art healthcare industry, Western Europe is projected to drive the Europe transdermal scopolamine market over the next few years.

Asia Pacific to Provide Most Promising Opportunities for Growth

With the increasing expenditure on healthcare, infrastructural developments in the healthcare industry, and the rising emphasis on community healthcare in emerging economies, such as China and India, Asia Pacific is expected to provide the most promising growth opportunities to players in the near future. The number of small- and medium- scale players, offering their transdermal scopolamine patches in this region, has increased substantially, making a competitive environment, which is likely to drive the Asia Pacific market for transdermal scopolamine further in the years to come. Amongst other, Latin America and the Middle East and Africa are anticipated to witness steady growth in their markets for transdermal scopolamine over the coming years, thanks to the rising number of travelers and the increasing focus of key industry players on these regions.

Baxter International Inc., GlaxoSmithKline Plc, Novartis AG, Perrigo Co. Plc, Caleb Pharmaceuticals Inc, and Myungmoon Pharma Co. Ltd. are the leading players operational in the global transdermal scopolamine market.

Global Transdermal Scopolamine Market: Overview

Scopolamine is an alkaloid, a secondary metabolite produced by plants of nightshade family such as henbane, Datura, Duboisia, etc. Scopolamine is used to treat motion sickness, and post-operative and anesthesia induced nausea and vomiting. It is often used to treat gastrointestinal spasm, irritable bowel syndrome and eye inflammation. Scopolamine is also used for nausea and vomiting prevention in chemotherapy for cancer treatment. Scopolamine can be administered orally as tablets or syrups, intravenously as injections and solutions, or as transdermal in form of patch or gel. Transdermal scopolamine is a scopolamine patch used to treat motion sickness and post-operative nausea and vomiting. Transdermal scopolamine available today are reservoir patches which can be used for up to 3 days. These patches are applied at back side of ear. These patches are applied 20 minutes to 4 hours before the intended use such as travel, surgery etc.

The first transdermal scopolamine patch was approved in 1979, manufactured by Alza Corporation and marketed by Novartis AG by brand name Transderm Scop. There are very few generics approved by FDA for Transderm Scop, which makes the market less competitive. Though there are few small players operating on regional level, however they hold a meager share in global transdermal scopolamine market. The global market for transdermal scopolamine is expected to grow at CAGR of 6.7% over the forecast period from 2016 to 2024. The launch of recently approved generics and projected expansion of international players is expected to drive the growth for this market. Moreover many of the industry players and researchers are investing on development of new transdermal scopolamine products.

Transdermal scopolamine is a preferred choice to treat motion sickness owing to its ease in administration, cost effectiveness and availability. Rise in number of travelers across globe is expected to drive the growth for transdermal scopolamine market over the forecast period. Moreover some of the industry players and researchers are investing on development of improved transdermal scopolamine patch on material, adhesion, drug bioavailability and other aspects. Expected introduction of such improved products coupled with launch of new entrants is expected to trigger the growth for transdermal scopolamine market. However there are few concern factors with transdermal scopolamine such as adverse effects, specifically the withdrawal symptoms which are anticipated to restrain growth.

Global Transdermal Scopolamine Market: Regional Outlook

Geographically, the transdermal scopolamine market has been segmented into five regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. These regions have been further segmented to country and sub-regional level. North America is expected to contribute largest share in global transdermal scopolamine market owing to high number of travelers, well established healthcare industry. Europe is expected to hold second position in global transdermal scopolamine market with growing number of surgeries and rising number of travelers.

The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global transdermal scopolamine market.

Companies Mentioned in the Report

The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Novartis AG, GlaxoSmithKline plc, Baxter International Inc., Perrigo Company plc, Caleb Pharmaceuticals, Inc., and Myungmoon Pharma Co. Ltd.

The global transdermal scopolamine market has been segmented as follows:

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa


 
 
Back To Top